Implantable cardioverter defibrillator and cardiac resynchronization therapy use in New Zealand (ANZACS‐QI 33)
Abstract Background The ANZACS‐QI Cardiac Implanted Device Registry (ANZACS‐QI DEVICE) collects nationwide data on cardiac implantable electronic devices in New Zealand (NZ). We used the registry to describe contemporary NZ use of implantable cardioverter defibrillator (ICD) and cardiac resynchroniz...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-02-01
|
| Series: | Journal of Arrhythmia |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/joa3.12244 |
| _version_ | 1818444065264369664 |
|---|---|
| author | Fang Shawn Foo Mildred Lee Khang‐Li Looi Peter Larsen Geoffrey C. Clare David Heaven Martin K. Stiles Jamie Voss Dean Boddington Rod Jackson Andrew J. Kerr on behalf of the ANZACS‐QI investigators |
| author_facet | Fang Shawn Foo Mildred Lee Khang‐Li Looi Peter Larsen Geoffrey C. Clare David Heaven Martin K. Stiles Jamie Voss Dean Boddington Rod Jackson Andrew J. Kerr on behalf of the ANZACS‐QI investigators |
| author_sort | Fang Shawn Foo |
| collection | DOAJ |
| description | Abstract Background The ANZACS‐QI Cardiac Implanted Device Registry (ANZACS‐QI DEVICE) collects nationwide data on cardiac implantable electronic devices in New Zealand (NZ). We used the registry to describe contemporary NZ use of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy (CRT). Methods All ICD and CRT Pacemaker implants recorded in ANZACS‐QI DEVICE between 1 January 2014 and 31 December 2017 were analyzed. Results Of 1579 ICD implants, 1152 (73.0%) were new implants, including 49.0% for primary prevention and 51.0% for secondary prevention. In both groups, median age was 62 years and patients were predominantly male (81.4% and 79.2%, respectively). Most patients receiving a primary prevention ICD had a history of clinical heart failure (80.4%), NYHA class II‐III symptoms (77.1%) and LVEF ≤35% (96.9%). In the secondary prevention ICD cohort, 88.4% were for sustained ventricular tachycardia or survived cardiac arrest from ventricular arrhythmia. Compared to primary prevention CRT Defibrillators (n = 155), those receiving CRT Pacemakers (n = 175) were older (median age 74 vs 66 years) and more likely to be female (38.3% vs 19.4%). Of the 427 (27.0%) ICD replacements (mean duration 6.3 years), 46.6% had received appropriate device therapy while 17.8% received inappropriate therapy. The ICD implant rate was 119 per million population with regional variation in implant rates, ratio of primary prevention ICD implants, and selection of CRT modality. Conclusion In contemporary NZ practice three‐quarters of ICD implants were new implants, of which half were for primary prevention. The majority met current guideline indications. Patients receiving CRT pacemaker were older and more likely to be female. |
| first_indexed | 2024-12-14T19:10:00Z |
| format | Article |
| id | doaj.art-55bf2a75f574470695198f0655688128 |
| institution | Directory Open Access Journal |
| issn | 1880-4276 1883-2148 |
| language | English |
| last_indexed | 2024-12-14T19:10:00Z |
| publishDate | 2020-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Arrhythmia |
| spelling | doaj.art-55bf2a75f574470695198f06556881282022-12-21T22:50:45ZengWileyJournal of Arrhythmia1880-42761883-21482020-02-0136115316310.1002/joa3.12244Implantable cardioverter defibrillator and cardiac resynchronization therapy use in New Zealand (ANZACS‐QI 33)Fang Shawn Foo0Mildred Lee1Khang‐Li Looi2Peter Larsen3Geoffrey C. Clare4David Heaven5Martin K. Stiles6Jamie Voss7Dean Boddington8Rod Jackson9Andrew J. Kerr10on behalf of the ANZACS‐QI investigatorsDepartment of Cardiology Middlemore Hospital Auckland New ZealandDepartment of Cardiology Middlemore Hospital Auckland New ZealandDepartment of Cardiology Auckland City Hospital Auckland New ZealandWellington Cardiovascular Research Group Wellington Hospital Wellington New ZealandDepartment of Cardiology Christchurch Hospital Christchurch New ZealandDepartment of Cardiology Middlemore Hospital Auckland New ZealandDepartment of Cardiology Waikato Hospital Hamilton New ZealandDepartment of Cardiology Middlemore Hospital Auckland New ZealandDepartment of Cardiology Tauranga Hospital Tauranga New ZealandUniversity of Auckland Auckland New ZealandDepartment of Cardiology Middlemore Hospital Auckland New ZealandAbstract Background The ANZACS‐QI Cardiac Implanted Device Registry (ANZACS‐QI DEVICE) collects nationwide data on cardiac implantable electronic devices in New Zealand (NZ). We used the registry to describe contemporary NZ use of implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy (CRT). Methods All ICD and CRT Pacemaker implants recorded in ANZACS‐QI DEVICE between 1 January 2014 and 31 December 2017 were analyzed. Results Of 1579 ICD implants, 1152 (73.0%) were new implants, including 49.0% for primary prevention and 51.0% for secondary prevention. In both groups, median age was 62 years and patients were predominantly male (81.4% and 79.2%, respectively). Most patients receiving a primary prevention ICD had a history of clinical heart failure (80.4%), NYHA class II‐III symptoms (77.1%) and LVEF ≤35% (96.9%). In the secondary prevention ICD cohort, 88.4% were for sustained ventricular tachycardia or survived cardiac arrest from ventricular arrhythmia. Compared to primary prevention CRT Defibrillators (n = 155), those receiving CRT Pacemakers (n = 175) were older (median age 74 vs 66 years) and more likely to be female (38.3% vs 19.4%). Of the 427 (27.0%) ICD replacements (mean duration 6.3 years), 46.6% had received appropriate device therapy while 17.8% received inappropriate therapy. The ICD implant rate was 119 per million population with regional variation in implant rates, ratio of primary prevention ICD implants, and selection of CRT modality. Conclusion In contemporary NZ practice three‐quarters of ICD implants were new implants, of which half were for primary prevention. The majority met current guideline indications. Patients receiving CRT pacemaker were older and more likely to be female.https://doi.org/10.1002/joa3.12244cardiac resynchronization therapydevice therapyimplant ratesImplantable cardioverter defibrillatorNew Zealand |
| spellingShingle | Fang Shawn Foo Mildred Lee Khang‐Li Looi Peter Larsen Geoffrey C. Clare David Heaven Martin K. Stiles Jamie Voss Dean Boddington Rod Jackson Andrew J. Kerr on behalf of the ANZACS‐QI investigators Implantable cardioverter defibrillator and cardiac resynchronization therapy use in New Zealand (ANZACS‐QI 33) Journal of Arrhythmia cardiac resynchronization therapy device therapy implant rates Implantable cardioverter defibrillator New Zealand |
| title | Implantable cardioverter defibrillator and cardiac resynchronization therapy use in New Zealand (ANZACS‐QI 33) |
| title_full | Implantable cardioverter defibrillator and cardiac resynchronization therapy use in New Zealand (ANZACS‐QI 33) |
| title_fullStr | Implantable cardioverter defibrillator and cardiac resynchronization therapy use in New Zealand (ANZACS‐QI 33) |
| title_full_unstemmed | Implantable cardioverter defibrillator and cardiac resynchronization therapy use in New Zealand (ANZACS‐QI 33) |
| title_short | Implantable cardioverter defibrillator and cardiac resynchronization therapy use in New Zealand (ANZACS‐QI 33) |
| title_sort | implantable cardioverter defibrillator and cardiac resynchronization therapy use in new zealand anzacs qi 33 |
| topic | cardiac resynchronization therapy device therapy implant rates Implantable cardioverter defibrillator New Zealand |
| url | https://doi.org/10.1002/joa3.12244 |
| work_keys_str_mv | AT fangshawnfoo implantablecardioverterdefibrillatorandcardiacresynchronizationtherapyuseinnewzealandanzacsqi33 AT mildredlee implantablecardioverterdefibrillatorandcardiacresynchronizationtherapyuseinnewzealandanzacsqi33 AT khanglilooi implantablecardioverterdefibrillatorandcardiacresynchronizationtherapyuseinnewzealandanzacsqi33 AT peterlarsen implantablecardioverterdefibrillatorandcardiacresynchronizationtherapyuseinnewzealandanzacsqi33 AT geoffreycclare implantablecardioverterdefibrillatorandcardiacresynchronizationtherapyuseinnewzealandanzacsqi33 AT davidheaven implantablecardioverterdefibrillatorandcardiacresynchronizationtherapyuseinnewzealandanzacsqi33 AT martinkstiles implantablecardioverterdefibrillatorandcardiacresynchronizationtherapyuseinnewzealandanzacsqi33 AT jamievoss implantablecardioverterdefibrillatorandcardiacresynchronizationtherapyuseinnewzealandanzacsqi33 AT deanboddington implantablecardioverterdefibrillatorandcardiacresynchronizationtherapyuseinnewzealandanzacsqi33 AT rodjackson implantablecardioverterdefibrillatorandcardiacresynchronizationtherapyuseinnewzealandanzacsqi33 AT andrewjkerr implantablecardioverterdefibrillatorandcardiacresynchronizationtherapyuseinnewzealandanzacsqi33 AT onbehalfoftheanzacsqiinvestigators implantablecardioverterdefibrillatorandcardiacresynchronizationtherapyuseinnewzealandanzacsqi33 |